IMARC Group, a leading market research company, has recently releases report titled “Blood Plasma Derivatives Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global blood plasma derivatives market size, growth, share, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Industry Overview of Blood Plasma Derivatives
Blood plasma derivatives are products obtained through the fractionation and purification of blood plasma, which is the liquid component of blood that remains after the removal of blood cells. They contain a variety of proteins, clotting factors, and antibodies that have specific medical uses. They consist of clotting factors for hemophilia treatment, immunoglobulins used in immunotherapy, and albumin solutions for volume replacement and wound healing. They can be produced by collecting plasma from donors, followed by a series of separation techniques like centrifugation and filtration.
How Big Is the Blood Plasma Derivatives Market?
The global blood plasma derivatives market size reached US$ 43.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 61.9 Billion by 2028, exhibiting a growth rate (CAGR) of 6.1% during 2023-2028.
Request Sample Copy of This Report: https://www.imarcgroup.com/blood-plasma-derivatives-market/requestsample
What are the growth prospects and trends in the blood plasma derivatives industry?
The increasing number of medical procedures, including surgeries and trauma cases, represents one of the primary factors driving the demand for blood plasma derivatives, which are essential for clotting and wound healing around the world.
Moreover, the growing prevalence of conditions like hemophilia, immune disorders, and liver diseases, especially among the elderly population, is offering a favorable market outlook. In addition, rising cases of autoimmune conditions, such as rheumatoid arthritis and multiple sclerosis, and significant improvements in the healthcare facilities and infrastructure are contributing to the market growth.
Apart from this, the growing awareness about rare diseases and improved diagnostic capabilities among the masses is creating a positive outlook for the market.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Type:
- Albumin
- Factor VIII
- Factor IX
- Immunoglobulin
- Hyperimmune Globulin
- Others
Breakup by Application:
- Hemophilia
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- Von Willebrand’s Disease
- Others
Breakup by End User:
- Hospitals
- Clinics
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
